Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cardiovascular disease

Venous thromboembolism (VTE); thrombosis

Factor Xa; thrombin (factor IIa; F2)

In vitro and rat studies identified a dual factor Xa and thrombin inhibitor that could help treat thrombosis. In vitro, the inhibitor, SAR107375, blocked both factor Xa and thrombin with low nanomolar potency. In a rat model of venous thrombosis, i.v. and oral dosing of SAR107375 had antithrombotic activity. In a rat model of arterial thrombosis, oral dosing of SAR107375 decreased bleeding compared with oral dosing of the factor Xa inhibitor Xarelto rivaroxaban or the thrombin inhibitor Pradaxa dabigatran and had comparable antithrombotic activity. Next steps include further assessing advantages of SAR107375 such as reduced bleeding risks relative to existing anticoagulants.
Boehringer Ingelheim GmbH markets the thrombin inhibitor Pradaxa to treat VTE.
Bayer AG and Johnson & Johnson market Xarelto to treat deep vein thrombosis (DVT), fibrillation, pulmonary embolism (PE), stroke and VTE.

SciBX 6(48); doi:10.1038/scibx.2013.1388
Published online Dec. 19, 2013

Patent application filed covering inhibitor; licensed to an undisclosed Chinese company

Meneyrol, J. et al. J. Med. Chem.; published online Oct. 31, 2013;
doi:10.1021/jm4005835
Contact: Gilbert Lassalle, Sanofi R&D, Toulouse, France
e-mail:
gilbert.lassalle@sanofi.com